nejm glp 1 publishes Phase 3 trial results for orforglipron, an oral GLP-1 obesity medication. | Scott Isaacs, MD, FACP, FACE posted on the topic Daily Oral GLP-1 Receptor Agonist

Am J Clin Nutr 2009

Overall, the therapeutic efficacy of TCM monomers in AR management by restoring the Th17/Treg imbalance has been demonstrated in the studies mentioned above, as summarized in Table 8

GAGs important for tissue hydration, growth factor binding, and structural support

There is an urgent need for a pharmacological agent that can specifically and safely correct the shared metabolic pathology, ideally by acting at both central (e.g., controlling appetite and cravings) and peripheral (e.g., improving insulin sensitivity, reducing hepatic fat and inflammation) levels to support and enhance existing behavioral strategies, thereby lowering the risk of advanced liver disease development across metabolic and alcoholic etiologies